Detalles de la búsqueda
1.
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
Cancer;
130(3): 421-432, 2024 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37846845
2.
Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
Haematologica;
109(2): 591-603, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37534514
3.
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM).
Ann Hematol;
103(4): 1305-1315, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38049586
4.
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Am J Hematol;
99(4): 523-533, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38247315
5.
Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation.
Ann Hematol;
102(11): 3195-3204, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37679605
6.
More accurate prediction of treatment response than mean apparent diffusion coefficient value in multiple myeloma using whole body MRI histogram analysis.
Future Oncol;
19(17): 1175-1185, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37386939
7.
YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
Blood;
136(4): 468-479, 2020 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32187357
8.
Prediction of Early Treatment Response in Multiple Myeloma Using MY-RADS Total Burden Score, ADC, and Fat Fraction From Whole-Body MRI: Impact of Anemia on Predictive Performance.
AJR Am J Roentgenol;
218(2): 310-319, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34523949
9.
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
Eur J Haematol;
105(3): 326-334, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32421883
10.
MAF translocation remains a strong prognostic factor despite concurrent chromosomal abnormalities.
Haematologica;
109(5): 1619-1623, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38235518
11.
Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial.
Haematologica;
109(5): 1614-1618, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205507
12.
Adenopathy and extensive skin patch overlying a plasmacytoma (AESOP) syndrome: a case report and literature review.
Ann Hematol;
103(1): 339-341, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743381
13.
Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy.
Br J Haematol;
191(1): 126-129, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32671820
14.
Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
Ann Hematol;
94(2): 257-64, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25231928
15.
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Biol Blood Marrow Transplant;
20(3): 319-25, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24296491
16.
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
Haematologica;
99(2): 353-9, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24213147
17.
Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
Ther Adv Med Oncol;
16: 17588359231221340, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38249329
18.
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Cancer Med;
13(2): e6965, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38348996
19.
Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
Leukemia;
38(6): 1299-1306, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38609496
20.
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Clin Cancer Res;
30(6): 1131-1142, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38170583